What does this research mean for the field?

JAK inhibitors are effective and well-tolerated for the treatment of vitiligo, with topical ruxolitinib supported as a first-line option for limited facial disease and oral agents showing promise. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of topical and oral Janus kinase (JAK) inhibitors compared with placebo or active comparators in patients with vitiligo.

August 30, 2026Journal of Dermatological TreatmentOpen Access

Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

ZLZiyi LinDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine YCYi ChenDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine JCJingpeng ChenDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Discussion

Member takes

Implication

Systematic review and meta-analysis demonstrates superior facial repigmentation with JAK inhibitors in vitiligo, indicating strong efficacy with comparable serious adverse event rates.

Key Points

To evaluate the efficacy and safety of topical and oral Janus kinase (JAK) inhibitors compared with placebo or active comparators in patients with vitiligo.
Systematic search across PubMed, Embase, Cochrane Library, and Web of Science through March 11, 2026, for RCTs evaluating JAK inhibitor monotherapy.
Included 9 RCTs encompassing 1,826 patients, with risk of bias evaluated using RoB 2.0 and evidence certainty graded using the GRADE framework.
JAK inhibitors significantly increased the achievement of 75% facial repigmentation (F-VASI75) versus placebo (RR 4.59, 95% CI 3.20–6.59; p < 0.001).
For F-VASI50, JAK inhibitors were superior to tacrolimus (RR 1.88, 95% CI 1.02–3.45) but not significantly different from dexamethasone (RR 2.17, 95% CI 0.95–4.94).
Serious adverse events did not differ significantly between JAK inhibitors and control groups (RR 1.15, 95% CI 0.57–2.33), with moderate-certainty evidence.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0696c1a8fb52e79c849 https://doi.org/10.1080/09546634.2026.2724628

View Full Paper

Ask AI

Bookmark

August 30, 2026Journal of Dermatological TreatmentOpen Access

Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Member takes

Implication

Systematic review and meta-analysis demonstrates superior facial repigmentation with JAK inhibitors in vitiligo, indicating strong efficacy with comparable serious adverse event rates.

Key Points

To evaluate the efficacy and safety of topical and oral Janus kinase (JAK) inhibitors compared with placebo or active comparators in patients with vitiligo.
Systematic search across PubMed, Embase, Cochrane Library, and Web of Science through March 11, 2026, for RCTs evaluating JAK inhibitor monotherapy.
Included 9 RCTs encompassing 1,826 patients, with risk of bias evaluated using RoB 2.0 and evidence certainty graded using the GRADE framework.
JAK inhibitors significantly increased the achievement of 75% facial repigmentation (F-VASI75) versus placebo (RR 4.59, 95% CI 3.20–6.59; p < 0.001).
For F-VASI50, JAK inhibitors were superior to tacrolimus (RR 1.88, 95% CI 1.02–3.45) but not significantly different from dexamethasone (RR 2.17, 95% CI 0.95–4.94).
Serious adverse events did not differ significantly between JAK inhibitors and control groups (RR 1.15, 95% CI 0.57–2.33), with moderate-certainty evidence.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0696c1a8fb52e79c849 https://doi.org/10.1080/09546634.2026.2724628

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark